JP2002535285A5 - - Google Patents

Download PDF

Info

Publication number
JP2002535285A5
JP2002535285A5 JP2000594485A JP2000594485A JP2002535285A5 JP 2002535285 A5 JP2002535285 A5 JP 2002535285A5 JP 2000594485 A JP2000594485 A JP 2000594485A JP 2000594485 A JP2000594485 A JP 2000594485A JP 2002535285 A5 JP2002535285 A5 JP 2002535285A5
Authority
JP
Japan
Prior art keywords
antibody
preparation
pharmaceutical composition
inhibiting
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000594485A
Other languages
English (en)
Japanese (ja)
Other versions
JP5066314B2 (ja
JP2002535285A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/001788 external-priority patent/WO2000043032A2/en
Publication of JP2002535285A publication Critical patent/JP2002535285A/ja
Publication of JP2002535285A5 publication Critical patent/JP2002535285A5/ja
Application granted granted Critical
Publication of JP5066314B2 publication Critical patent/JP5066314B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000594485A 1999-01-25 2000-01-25 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用 Expired - Lifetime JP5066314B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11716999P 1999-01-25 1999-01-25
US60/117,169 1999-01-25
US14322899P 1999-07-09 1999-07-09
US60/143,228 1999-07-09
PCT/US2000/001788 WO2000043032A2 (en) 1999-01-25 2000-01-25 Baff, inhibitors thereof and their use in the modulation of b-cell response

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008303135A Division JP4955642B2 (ja) 1999-01-25 2008-11-27 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2012077812A Division JP2012126749A (ja) 1999-01-25 2012-03-29 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2002535285A JP2002535285A (ja) 2002-10-22
JP2002535285A5 true JP2002535285A5 (https=) 2009-01-22
JP5066314B2 JP5066314B2 (ja) 2012-11-07

Family

ID=26815006

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000594485A Expired - Lifetime JP5066314B2 (ja) 1999-01-25 2000-01-25 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2008303135A Expired - Fee Related JP4955642B2 (ja) 1999-01-25 2008-11-27 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2012012379A Withdrawn JP2012087145A (ja) 1999-01-25 2012-01-24 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2012077812A Pending JP2012126749A (ja) 1999-01-25 2012-03-29 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2014090152A Pending JP2014141527A (ja) 1999-01-25 2014-04-24 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2008303135A Expired - Fee Related JP4955642B2 (ja) 1999-01-25 2008-11-27 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2012012379A Withdrawn JP2012087145A (ja) 1999-01-25 2012-01-24 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2012077812A Pending JP2012126749A (ja) 1999-01-25 2012-03-29 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用
JP2014090152A Pending JP2014141527A (ja) 1999-01-25 2014-04-24 免疫応答におけるb細胞および免疫グロブリンの刺激および阻害における、baff、関連するブロック剤およびそれらの使用

Country Status (29)

Country Link
US (1) US6869605B2 (https=)
EP (5) EP1146892B1 (https=)
JP (5) JP5066314B2 (https=)
KR (1) KR100834809B1 (https=)
CN (1) CN100340292C (https=)
AT (2) ATE515267T1 (https=)
AU (1) AU762839B2 (https=)
BR (1) BR0007719A (https=)
CA (1) CA2360062A1 (https=)
CY (2) CY1107453T1 (https=)
CZ (1) CZ299819B6 (https=)
DE (1) DE60004635T2 (https=)
DK (2) DK1146892T3 (https=)
EA (1) EA006108B1 (https=)
EE (1) EE05699B1 (https=)
ES (1) ES2204528T3 (https=)
HK (1) HK1040628B (https=)
HU (1) HUP0105283A3 (https=)
IL (3) IL144202A0 (https=)
IS (1) IS5993A (https=)
MX (1) MXPA01007464A (https=)
NO (2) NO20013641L (https=)
NZ (1) NZ513284A (https=)
PL (1) PL198934B1 (https=)
PT (2) PT1415659E (https=)
SI (1) SI1146892T1 (https=)
SK (1) SK286665B6 (https=)
TR (2) TR200102147T2 (https=)
WO (1) WO2000043032A2 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
EP0878552A1 (en) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
JP2002513587A (ja) 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU8506601A (en) * 2000-08-18 2002-03-04 Dyax Corp Binding polypeptides for b lymphocyte stimulator protein (blys)
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
CA2465268A1 (en) * 2001-10-24 2003-05-01 National Jewish Medical And Research Center Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
WO2004011611A2 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
US20070010658A1 (en) * 2002-10-29 2007-01-11 Holtet Thor L Trimeric binding proteins for trimeric cytokines
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004074511A1 (en) * 2003-02-21 2004-09-02 Garvan Institute Of Medical Research Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
CA2523776A1 (en) * 2003-03-07 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
JP2007526220A (ja) * 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド B細胞疾患の併用療法
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007509064A (ja) 2003-10-20 2007-04-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Baffアンタゴニストのための治療養生法
US20070249530A1 (en) 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
JP5570681B2 (ja) * 2004-08-31 2014-08-13 興和株式会社 抗ヒトbaff抗体
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
US20090232808A1 (en) * 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
WO2006081516A2 (en) * 2005-01-28 2006-08-03 Biogen Idec Ma Inc. USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2006125140A2 (en) * 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007142667A2 (en) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AU2011226689B2 (en) * 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
CZ2012561A3 (cs) * 2012-08-22 2013-10-23 Masarykova Univerzita B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
EP2971077B1 (en) 2013-03-15 2019-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
KR101493592B1 (ko) 2013-04-29 2015-02-17 부산대학교 산학협력단 Socs3 단백질을 이용한 baff 연관 면역질환 치료제 스크리닝 방법
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
EP3313429B1 (en) * 2015-06-19 2021-10-06 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection
CN107328620B (zh) * 2017-06-23 2020-06-05 浙江普罗亭健康科技有限公司 用于流式细胞技术的封闭缓冲液及试剂盒
WO2019126366A2 (en) * 2017-12-19 2019-06-27 The Johns Hopkins University Baff therapy to promote anti- tumor immunity
US20210238295A1 (en) * 2018-04-26 2021-08-05 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU726486C (en) 1996-03-14 2004-02-05 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
SE505941C2 (sv) 1996-10-29 1997-10-27 Bjoern Hellstroem Klämskyddslist
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
JP2002504818A (ja) * 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ,インコーポレイテッド リガンドファミリーのntn−2メンバー
AU7608898A (en) 1997-06-06 1998-12-21 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1012270A2 (en) 1997-09-12 2000-06-28 Apotech R&D S.A. Kay - a novel immune system protein
CZ294615B6 (cs) 1997-09-12 2005-02-16 Apotech R & D Sa Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
SI1642972T1 (sl) 1999-01-07 2010-05-31 Zymogenetics Inc Terapevtske uporabe BR X topnih receptorjev
IL144202A0 (en) * 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
CA2363112A1 (en) 1999-02-23 2000-08-31 Craig A. Rosen Neutrokine-alpha and neutrokine-alpha splice variant
EP1157126A4 (en) 1999-02-24 2005-03-02 Gen Hospital Corp METHOD FOR CLONING INTERMEDIATE SIGNAL TRANSDUCTION PRODUCTS
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CA2897626C (en) * 2000-02-11 2020-03-24 Biogen Ma Inc. Heterologous polypeptide of the tnf family
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
WO2002018620A2 (en) 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys

Similar Documents

Publication Publication Date Title
JP2002535285A5 (https=)
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
JP2001515712A5 (https=)
JP2003503361A5 (https=)
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
ATE541860T1 (de) Humane antikörper gegen cd40 zur therapie von b- zell tumoren
JP2004501101A5 (https=)
DE69709632D1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
NZ601544A (en) Combination therapy for the treatment of ocular neovascular disorders
DE69734317D1 (de) Anti-tnf antikörper / tnf rezeptor und methotrexat zur behandlung von autoimmunkrankheiten
EP1245676A4 (en) HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE
WO2001078779A3 (en) Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
JP2020510039A5 (https=)
JP2004537500A5 (https=)
RU2004137823A (ru) Терапевтическое средство против гиперкальциемического криза
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
Marshall et al. Effects of coumarin (1, 2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies
US6288074B1 (en) Method of treating lymphoproliferative syndrome
WO2002026193A3 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
WO2005058966A3 (en) Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases
CN1208643A (zh) 一种治疗前列腺疾病的药物及其制备方法
JPH11279199A5 (https=)
Simmons When paradigms fall: the demise of" hit hard, hit early"
Nicoletti Observations on Results Achieved in 25,000 Patients Treated with Both Acupuncture and Homeopathy
RU2004121622A (ru) Способ лечения субинволюции матки у коров